The right drug at the right dose and right time

Digital Therapeutics platform uses predictive analytics to accelerate
diagnostics and treatment of infectious diseases

Our Mission

At Luminacare, our mission is to help advance the diagnostics and treatment of multi-drug resistant bacterial infections. We aim to integrate knowledge from infectious disease research, drug discovery, data modeling and software development to advance treatment techniques against bacterial drug-resistant infections.

Our Team

Our team brings in extensive experience in diverse backgrounds from modeling and simulation of drug exposures and outcomes, data analytics, clinical infectious disease management, and software development and delivery and healthcare operations.

Dr. David Howe

Co-Founder & CEO

As CEO and co-founder of LuminaCare Solutions, Dr. Howe is responsible for overseeing the company’s strategic business direction and driving the scientific and technical vision for the company. With more than 15 years of experience in the pharmaceutical industry, Dr. Howe has held leadership positions at Vertex Pharmaceuticals and AstraZeneca. In these positions, he has led teams guiding drug discovery and development efforts through expertise on drug metabolism, pharmacokinetics, and pharmacokinetic/ pharmacodynamics for antibacterial programs and various disease areas. He has experience in the design and support of preclinical and clinical trials through Phase III for antibacterials. Dr. Howe holds his PhD in Medicinal Chemistry from the University of Michigan where he investigated the enzymatic mechanisms of novel biological targets to design new antibacterials for gram-negative bacteria. He has his B.S.E in Aerospace Engineering.

Stephen Chiricosta

Co-Founder & COO

Stephen R. Chiricosta- As COO and co-founder of LuminaCare Solutions, Mr. Chiricosta is responsible for overseeing the company’s business operations, including corporate strategy, market segmentation, communication and operations. Since co-founding LCS in January 2013, Mr. Chiricosta has secured acceptance for the company into WilmerHale’s QuickStart Program, The Venture Development Center at the University of Massachusetts, Boston, and IBM’s Global Entrepreneurship Program. Prior to LuminaCare solutions, Mr. Chiricosta held various positions in the biotech and pharmaceutical industries, including Business Development Executive at BioPharma Technology LLC. As an experienced business professional, Mr. Chiricosta has a strong track record of results, execution and excellence. He has his B.S. in Biology from the University of Massachusetts, Amherst.

Ragu Bharadwaj

CTO

As CTO of LuminaCare Solutions, Dr. Bharadwaj is responsible for implementing the company’s strategic vision, via its technology platform. Dr. Bharadwaj has held leadership positions at Daylight Chemical Information Systems, Vertex Pharmaceuticals and most recently Topcoder. He has either worked in or led teams solving complex problems including drug discovery in Cystic Fibrosis, problems in computer vision, robotics, audio language recognition. Dr. Bharadwaj holds his PhD in Biochemistry & Molecular Biophysics from Columbia University and a SM in Systems Design and Management from the Massachusetts Institute of Technology.

Advisors

Kenneth Getz

Advisor

Mr. Getz is a serial entrepreneur of several ventures serving clinical research stakeholder with expertise in quantitative analysis of clinical research and healthcare market trends and practices. He is Director of Sponsored Research Programs and Research Associate Professor at Tufts University School of Medicine. Mr. Getz received his MBA from Northwestern University – Kellogg School of Management and a B.A. from Brandeis University.

Steven Schmidt

Advisor

Mr. Schmidt is a seasoned senior level executive and serial entrepreneur. Mr. Schmidt has 25 years in the pharmaceutical industry where he has held senior executive positions and was Chief Information Officer at Vertex Pharmaceuticals. Mr. Schmidt has expertise in starting and growing businesses, informatics and healthcare information technology. Mr. Schmidt received his MS in Organic Chemistry from the San Diego State University – California State University and B.S. for University of Wisconsin-Madison.

Dr. Tawanda Gumbo

Advisor

Dr. Gumbo is the Director of the Center of Infectious Diseases and Experimental Therapeutics at the Baylor Research Institute. Previously, Dr. Gumbo was the Administrative Director of Research Program in Global Health and Associate Professor at the University of Texas Southwestern Medical Center. Dr. Gumbo has led efforts to understand antibiotic selection and dosing for TB and other bacterial infections. He was a Fellow in Infectious Disease at Cleveland Clinic and Train in Pharmacometrics at Ordway Research Institute in Albany, NY.

David McFarlane

Advisor

Mr. McFarlane has over 25 years experience in operations, global sales and marketing, business development and information technology. Prior to Litmus, he has held multiple C level positions overseeing early stage companies through scaled execution to successful IPOs and M& A exits.

Dr. Jahan Ali

Advisor

Dr. Jahan Ali is a founder of Octane Ventures, which helps bioscience and health IT companies grow their businesses and meet milestones. Jahan has spent the last 16 years on various sides of early stage biotechnology commercialization and startups. Most recently, she was the Senior Vice President at the Partnership Fund for New York City Investment Fund, a private economic development fund founded by Henry Kravis, where she managed the fund’s investments in the healthcare sector. While there, Jahan led the BioAccelerate NYC.

John Hamilton

Advisor

John Hamilton is an accomplished executive with over 25+ years’ experience managing early stage startups to large company IPOs. Hamilton has vast sales and marketing expertise that has spanned several well-known Boston based companies from Stratus Computer, EMC, FTP Software, Concord Communications, Phase Forward, XKoto and Viewfinity. His ability to prepare companies for acquisition and or IPO has yielded significant returns for shareholders across the board.

Collaborators

Jacaranda Biomed

Collaborating on development of cloud-based software for the treatment of tuberculosis.

Quvium

Collaborating on development of cloud-based software for the treatment of bacterial infections with patients with COPD and asthma.